View Older Stories View More Recent Stories

Sep 27, 2024 04:05PM Savara Announces New Employment Inducement Grant
Sep 27, 2024 08:05AM Savara (SVRA) Announces Expanded Access Program for Molgramostim Inhalation Solution for Patients with Autoimmune Pulmonary Alveolar Proteinosis
Sep 27, 2024 08:05AM Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Sep 24, 2024 08:05AM Savara (SVRA) Appoints Braden Parker as Chief Commercial Officer
Sep 24, 2024 08:05AM Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
Sep 23, 2024 08:05AM Savara to Host Analyst and Investor Webinar on September 30, 2024
Sep 9, 2024 06:13AM Savara (SVRA) Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution
Sep 8, 2024 06:45AM Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the
Sep 6, 2024 04:05PM Savara Announces New Employment Inducement Grant
Sep 3, 2024 04:05PM Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 16, 2024 04:05PM Savara Announces New Employment Inducement Grant
Aug 15, 2024 08:05AM Savara (SVRA) to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis
Aug 15, 2024 08:05AM Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respi
Aug 12, 2024 04:05PM Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
Jun 26, 2024 06:32AM Savara (SVRA) Reports Molgramostim Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2
Jun 26, 2024 06:30AM Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in
Jun 25, 2024 08:05PM Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosi
May 29, 2024 08:05AM Savara to Present at the Jefferies Global Healthcare Conference
May 19, 2024 12:15PM Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
May 16, 2024 04:05PM Savara Announces New Employment Inducement Grant
May 9, 2024 04:05PM Savara Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024 04:05PM Savara to Present at the Citizens JMP Life Sciences Conference
Apr 8, 2024 08:05AM Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Mar 22, 2024 04:05PM Savara Announces New Employment Inducement Grant
Mar 7, 2024 04:05PM Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Mar 6, 2024 04:05PM Savara to Present at the Barclays 26th Annual Global Healthcare Conference
Feb 2, 2024 08:05AM Savara Announces New Employment Inducement Grant
Jan 31, 2024 08:05AM Savara to Present at Two Upcoming Healthcare Conferences
Dec 21, 2023 08:05AM Savara (SVRA) Introduces aPAP ClearPath
Dec 21, 2023 08:05AM Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Dec 20, 2023 08:05AM Savara Added to the NASDAQ Biotechnology Index
Dec 15, 2023 04:05PM Savara Announces New Employment Inducement Grant
Nov 21, 2023 08:05AM Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
Nov 9, 2023 04:05PM Savara Reports Third Quarter Financial Results and Provides Business Update
Nov 8, 2023 04:05PM Savara to Present at the Jefferies London Healthcare Conference
Oct 6, 2023 04:05PM Savara Announces New Employment Inducement Grant
Sep 5, 2023 04:05PM Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 10, 2023 04:05PM Savara Reports Second Quarter Financial Results and Provides Business Update
Aug 4, 2023 04:05PM Savara Announces New Employment Inducement Grant
Jun 26, 2023 04:07PM Savara (SVRA) added to Russell 3000
Jun 26, 2023 04:05PM Savara Added to Russell 3000® Index
Jun 26, 2023 08:05AM Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Jun 2, 2023 08:05AM Savara to Present at the Jefferies Healthcare Conference
May 15, 2023 08:05AM Savara Reports First Quarter Financial Results and Provides Business Update
May 5, 2023 04:05PM Savara Announces New Employment Inducement Grant
Mar 31, 2023 04:05PM Savara Announces New Employment Inducement Grant
Mar 30, 2023 04:05PM Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update
Mar 6, 2023 04:05PM Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 28, 2023 04:05PM Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Feb 14, 2023 08:05AM Savara (SVRA) Announces Leadership Appointments
View More Recent Stories View Older Stories